I am somewhat reserved about the claim by Jason Shafrin that a reduction in patent length will harm social welfare.
First of all, drug companies already use a variety of devious techniques to extend their monopoly pricing. Just look up pay-for-delay, product-hopping, et al. It is not quite the benign world of social good that Shafrin assumes.
Secondly, I am not sure that all drug spending automatically creates social welfare. The drug Sovaldi can cure Hepatitis C, which means that drug addicts live longer. I am not sure that is pure social welfare.
I am somewhat reserved about the claim by Jason Shafrin that a reduction in patent length will harm social welfare.
First of all, drug companies already use a variety of devious techniques to extend their monopoly pricing. Just look up pay-for-delay, product-hopping, et al. It is not quite the benign world of social good that Shafrin assumes.
Secondly, I am not sure that all drug spending automatically creates social welfare. The drug Sovaldi can cure Hepatitis C, which means that drug addicts live longer. I am not sure that is pure social welfare.